Antithrombotic Drug Therapy in Cardiovascular Disease 1st Edition by Edward F Plow, Peter Kelly, Arman T Askari, A Michael Lincoff ISBN 1603272348 9781603272346

Antithrombotic Drug Therapy in Cardiovascular Disease 1st Edition by Edward F Plow, Peter Kelly, Arman T Askari, A Michael Lincoff – Ebook PDF Instant Download/Delivery: 1603272348, 9781603272346
Full download Antithrombotic Drug Therapy in Cardiovascular Disease 1st Edition after payment

Product details:

ISBN 10: 1603272348 
ISBN 13: 9781603272346
Author: Edward F Plow, Peter Kelly, Arman T Askari, A Michael Lincoff

Antithrombotic Drug Therapy in Cardiovascular Disease 1st Table of contents:

1 Platelets in Arterial Thrombosis
PLATELETS IN THROMBUS FORMATION
PLATELET ADHESION AND ITS RECEPTORS
Platelet-Collagen Interactions
GPIb-IX-V
GPVI
Integrin a2b1
Other Adhesion Receptors
AGONIST RECEPTORS
ADP Receptors
P2Y1 Receptors
P2Y12 Receptors
P2X1 Receptors
PROTEASE-ACTIVATED RECEPTORS
THROMBOXANE A2 RECEPTORS
PLATELET AGGREGATION AND ITS RECEPTORS
aIIbb3
Modulators of Platelet Aggregation
REFERENCES

2 The Role of Coagulation in Arterial and Venous Thrombosis
INTRODUCTION
CLINICAL MANIFESTATIONS OF ARTERIAL AND VENOUS THROMBOSIS
COAGULATION PHYSIOLOGY
The Intrinsic Pathway
The Extrinsic Pathway
Fibrin Formation and Common Pathway Activation
Lessons from Studying In Vivo Coagulation Activation
REGULATION OF COAGULATION
Regulation of Tissue Factor
Regulation of Thrombin
Protein Z System
Role of Endothelium
Role of Microparticles
Interaction Between Coagulation and Platelet Activation
COAGULATION DYSREGULATION IN ARTERIAL AND VENOUS THROMBOSIS
Coagulation Dysregulation and Venous Thromboembolic Disease
Congenital Thrombophilia
Factor V Leiden
Prothrombin G20210A
Acquired Thrombophilia
The Role of Coagulation in Arterial Disease
Links Between Coagulation and Atherosclerosis
Role of Thrombophilia Risk Factors in Arterial Thrombosis
SUMMARY
References

3 The Link Between Inflammation and Thrombosis
PATHOBIOLOGY OF INFLAMMATION, ATHEROSCLEROSIS, AND ACS
Endothelial Function
Adhesion Molecules
Cellular and Humoral-Mediated Response
Monocytes and Macrophages
Mast Cells
Neutrophils
Platelets
Chemokines and Cytokines
Chemokines
Tumor Necrosis Factor-a
Interleukins
CD40 and CD4OL
Nuclear Transcription Factors
NF-kB
PPAR
Other Mediators
Myeloperoxidase
A2 Phospholipases
Angiogenic Growth Factors
MARKERS AND MEDIATORS OF INFLAMMATION
C-Reactive Protein and Serum Amyloid A
THE FUTURE OF INFLAMMATION CONTROL IN ACS
Aspirin
HMG-CoA Reductase Inhibitors (Statins)
ACE Inhibitors
Thrombin Receptor Antagonists
Inhibition of Cell-to-Cell Interaction
CLOSING THOUGHTS AND CAUTIONARY ACCOUNTS FROM PREVIOUS ANTI-INFLAMMATORY STRATEGIES
REFERENCES

4 The Genetics of Thrombosis
INTRODUCTION
Evidence For a Genetic Basis To Thrombosis
The Evolutionary Basis of Coagulation
THE GENETICS OF COAGULATION AND THROMBOSIS IN HUMANS
Linkage Analysis To Define Genetics Of Thrombosis
Association Studies In Genetics Of Thrombosis
GENETIC VARIANTS IMPLICATED IN VENOUS THROMBOTIC DISORDERS
Antithrombin III Deficiency
Protein S Deficiency
Protein C Deficiency
Activated Protein C Resistance (Factor V Leiden)
Other Forms of Activated Protein C Deficiencies
Prothrombin 20210A
Hyperhomocysteinemia
Lupus Anticoagulant/Antiphospholipid Antibodies
Other Genetic Factors Associated with VTE
Laboratory Assays and Diagnostic Testing for Hereditary VTE
GENETIC VARIANTS IN ARTERIAL THROMBOTIC DISORDERS
Genetic Variants In Hemostatic System Genes
Fibrinogen
Factor V Leiden and Prothrombin G20210A
Other Coagulation Proteins And Arterial Thrombosis Risk
Genetic Variants In Platelet Surface Receptors
Genetic Variants In The Fibrinolytic System
Other Mechanisms Of Genetic Risk For Arterial Thrombosis
GENETIC BASIS FOR RELATIONSHIP BETWEEN ARTERIAL AND VENOUS THROMBOTIC RISK
PHARMACOGENOMICS
Pharmacogenetics of Resistance To Antiplatelet Agents
Pharmacogenetics of Fibrinolytic Therapies
Pharmacogenetics of Warfarin
CLINICAL CONSIDERATIONS IN INHERITED THROMBOTIC DISORDERS
Clinical Manifestations of Hereditary Thrombotic Disorders
Screening Considerations
Implications For Treatment
Initial Treatment of VTE
Long-Term Anticoagulation
Management of Pregnancy
Other Management Considerations
COMPLEX DISEASE GENETICS
Gene–Environment Interactions
Vascular-Bed Specific Factors
Gene–Gene Interactions
Beyond Genetics
Transcriptomics
Proteomics
Considerations In Genomic Studies
Conclusions
REFERENCES

5 Aspirin in Primary and Secondary Prevention of Cardiovascular Disease
HISTORY OF ASPIRIN
PHARMACOKINETICS
MECHANISM OF ACTION
ASPIRIN FOR CARDIOVASCULAR PREVENTION
Secondary Prevention
Primary Prevention
ADVERSE EFFECTS OF LOW-DOSE ASPIRIN
ASPIRIN MAY NOT ALWAYS WORK
RECOMMENDATIONS
REFERENCES

6 Thienopyridines in Stable Coronary Disease
INTRODUCTION
THIENOPYRIDINES
BRIEF REVIEW OF THIENOPYRIDINE TRIALS
THE CHARISMA TRIAL
POOLED ANALYSIS OF LARGE TRIALS OF CLOPIDOGREL PLUS ASPIRIN
ADDITIONAL ANALYSES FROM CHARISMA
THIENOPYRIDINES IN STABLE CORONARY ARTERY DISEASE
SHOULD DUAL ANTIPLATELET TREATMENT BE STARTED IN STABLE PATIENTS?
DISCUSSION
REFERENCES

7 Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction
INTRODUCTION
PLATELETS: CONNECTING INFLAMMATION AND THROMBOSIS
CURRENT ANTIPLATELET THERAPIES IN NON-ST-SEGMENT MYOCARDIAL INFARCTION
Aspirin
Aspirin Dosing
ADP Receptor Blockade (Thienopyridines)
Ticlopidine
Clopidogrel
Drug Eluting Stent Thrombosis and Clopidogrel Therapy
Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Novel Antiplatelet Therapies on the Horizon
Conclusion
REFERENCES

8 Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary
STRUCTURE AND MECHANISM OF ACTION
PHARMACOKINETICS
HEPARIN MONITORING AND DOSING
UFH
Enoxaparin
CLINICAL TRIALS OF UFH IN NSTE ACS
CLINICAL TRIALS OF LMWH IN NSTE ACS
Trials of LMWH versus Placebo
Trials with LMWH versus UFH
First Large Randomized Clinical Trials of Enoxaparin versus UFH In NSTE ACS
Trials of LMWH versus UFH In Addition to a GP IIb/IIIa Inhibitor
Trials of LMWH versus UFH In Patients Undergoing an Early Invasive Strategy
OVERVIEW OF TRIALS COMPARING LMWH AND UFH IN NSTE ACS
MANAGEMENT OF ANTITHROMBIN THERAPY DURING PCI IN NSTE ACS PATIENTS
CLINICAL PERSPECTIVE AND CURRENT GUIDELINE RECOMMENDATIONS
REFERENCES

9 Direct Thrombin Inhibitors in Acute Coronary Syndromes
INTRODUCTION
OVERVIEW OF DIRECT THROMBIN INHIBITORS
SPECIFIC DIRECT THROMBIN INHIBITORS
Hirudin
Bivalirudin
Argatroban
Orally Active Direct Thrombin Inhibitors
Clinical Use of Direct Thrombin Inhibitors in Unstable Angina and NSTEMI
Clinical Use of Direct Thrombin Inhibitors in STEMI
Safety and Efficacy of Switching Anticoagulant Therapy
Recommendations for Use of Direct Thrombin Inhibitors in ACS
UA/NSTEMI
STEMI
Summary
REFERENCES

10 Synthetic Factor Xa Inhibition in Acute Coronary Syndromes
INTRODUCTION
FONDAPARINUX SODIUM – SELECTIVE FACTOR XA INHIBITOR
FONDAPARINUX IN ACS – CLINICAL TRIALS
Percutaneous Coronary Intervention
OASIS-5 – UA/NSTEMI
OASIS-6 – STEMI
ACC UA/NSTEMI GUIDELINES – UPDATE 2007
COST-ANALYSIS OF FONDAPARINUX IN ACS
CONCLUSION
REFERENCES

11 Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibito
BACKGROUND
ASPIRIN
THIENOPYRIDINES
Pharmacologic Reperfusion
Mechanical Reperfusion
GLYCOPROTEIN (GP) IIb/IIIa RECEPTOR INHIBITORS

People also search for Antithrombotic Drug Therapy in Cardiovascular Disease 1st:

antithrombotic drugs for stroke
    
antithrombotic therapy in peripheral artery disease
    
antithrombotic drugs examples
    
antithrombotic drugs mechanism of action
    
anti-thrombotic drug

Tags: Edward F Plow, Peter Kelly, Arman T Askari, A Michael Lincoff, Antithrombotic Drug, Cardiovascular